AstraZeneca_NNP Annual_JJ Report_NNP and_CC IFRS_NNP Restatements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 139_CD IFRS_NNP Restatements_NNP Introduction_NNP to_TO be_VB taken_VBN directly_RB to_TO reserves_NNS ,_, as_RB is_VBZ payments_NNS and_CC milestones_NNS ,_, are_VBP capitalized_VBN AstraZeneca_NNP currently_RB prepares_VBZ its_PRP$ primary_JJ required_VBN under_IN FRS_NNP 17_CD Retirement_NNP and_CC amortised_VBN over_IN their_PRP$ economic_JJ lives_NNS from_IN financial_JJ statements_NNS under_IN UK_NNP Generally_RB Benefits_NNPS ._.
Intangible_JJ assets_NNS relating_VBG to_TO products_NNS Accepted_JJ Accounting_NN Principles_NNPS UK_NNP GAAP_NNP ._.
endorsed_VBN by_IN the_DT EU_NNP ,_, will_MD be_VB effective_JJ for_IN in_IN development_NN both_DT internally_RB generated_VBN From_IN 2005_CD onwards_NNS the_DT Group_NNP will_MD be_VB accounting_VBG periods_NNS commencing_VBG on_IN or_CC and_CC externally_RB acquired_VBN are_VBP subject_JJ to_TO required_VBN to_TO prepare_VB its_PRP$ consolidated_JJ financial_JJ after_IN 1_CD January_NNP 2006_CD ,_, with_IN earlier_JJR impairment_NN testing_NN at_IN each_DT balance_NN sheet_NN statements_NNS in_IN accordance_NN with_IN International_NNP adoption_NN encouraged_VBN by_IN the_DT IASB_NNP ._.
date_NN or_CC earlier_JJR upon_IN indication_NN of_IN impairment_NN ._.
Accounting_NNP Standards_NNPS IAS_NNP and_CC International_NNP AstraZeneca_NNP has_VBZ adopted_VBN the_DT provisions_NNS Any_DT impairment_NN losses_NNS are_VBP written_VBN off_RP Financial_NNP Reporting_NNP Standards_NNPS IFRS_NNP as_IN of_IN this_DT amendment_NN in_IN its_PRP$ restated_VBN immediately_RB to_TO income_NN ._.
adopted_VBN by_IN the_DT European_NNP Union_NNP EU_NNP ._.
change_NN applies_VBZ to_TO all_DT financial_JJ reporting_NN for_IN IFRS_NNP 2_CD ,_, IFRS_NNP 6_CD and_CC various_JJ IFRIC_NNP Business_NNP combinations_NNS and_CC goodwill_NN accounting_NN periods_NNS beginning_VBG on_IN or_CC after_IN interpretations_NNS and_CC amendments_NNS to_TO On_IN the_DT acquisition_NN of_IN a_DT business_NN ,_, fair_JJ values_NNS 1_CD January_NNP 2005_CD and_CC ,_, consequently_RB ,_, SIC_NNP 12_CD have_VBP not_RB yet_RB been_VBN endorsed_VBN ._.
are_VBP attributed_VBN to_TO the_DT net_JJ assets_NNS acquired_VBN ._.
AstraZenecas_NNP first_JJ IFRS_NNP results_NNS will_MD be_VB its_PRP$ Goodwill_NNP arises_VBZ where_WRB the_DT fair_JJ value_NN of_IN the_DT interim_JJ results_NNS for_IN Q1_NNP 2005_CD ._.
The_DT Groups_NNS first_JJ Accounting_NN policies_NNS consideration_NN given_VBN for_IN a_DT business_NN exceeds_VBZ Annual_JJ Report_NNP under_IN IFRS_NNP will_MD be_VB for_IN 2005_CD ._.
the_DT fair_JJ value_NN of_IN such_JJ net_JJ assets_NNS ._.
As_IN the_DT Group_NNP publishes_VBZ comparative_JJ Basis_NN of_IN accounting_VBG information_NN for_IN two_CD years_NNS in_IN its_PRP$ Annual_JJ As_IN set_VBN out_RP in_IN the_DT Basis_NN of_IN Preparation_NNP ,_, the_DT Goodwill_NNP arising_VBG on_IN acquisitions_NNS is_VBZ capitalized_VBN Report_NNP ,_, the_DT date_NN for_IN transition_NN to_TO IFRS_NNP is_VBZ restated_VBN financial_JJ information_NN on_IN pages_NNS 139_CD and_CC subject_JJ to_TO impairment_NN review_NN ,_, both_DT 1_CD January_NNP 2003_CD ,_, this_DT being_VBG the_DT start_NN of_IN the_DT to_TO 146_CD ,_, has_VBZ been_VBN prepared_VBN in_IN accordance_NN annually_RB and_CC when_WRB there_EX are_VBP indications_NNS that_WDT earliest_JJS period_NN of_IN comparative_JJ information_NN ._.
with_IN IAS_NNP and_CC IFRS_NNP as_IN adopted_VBN by_IN the_DT EU_NNP ._.
the_DT carrying_VBG value_NN may_MD not_RB be_VB recoverable_JJ ._.
Prior_RB to_TO 1_CD January_NNP 2003_CD ,_, goodwill_NN was_VBD To_TO explain_VB how_WRB AstraZenecas_NNP reported_VBD The_DT accounting_NN policy_NN for_IN financial_JJ amortised_VBN over_IN its_PRP$ estimated_VBN useful_JJ life_NN :_: such_JJ performance_NN and_CC financial_JJ position_NN are_VBP instruments_NNS complies_NNS with_IN the_DT EU_NNP carve_VB out_RP amortisation_NN ceased_VBD on_IN 31_CD December_NNP 2002_CD ._.
affected_VBN by_IN this_DT change_NN ,_, information_NN version_NN of_IN IAS_NNP 39_CD ._.
The_DT policies_NNS also_RB assume_VBP previously_RB published_VBN under_IN UK_NNP GAAP_NNP is_VBZ that_IN the_DT amendments_NNS to_TO IAS_NNP 19_CD Employee_NNP The_DT Groups_NNS policy_NN up_IN to_TO and_CC including_VBG 1997_CD restated_VBN under_IN IFRS_NNP on_IN pages_NNS 139_CD to_TO 146_CD ._.
Benefits_NNS published_VBN in_IN December_NNP 2004_CD by_IN the_DT was_VBD to_TO eliminate_VB goodwill_NN arising_VBG upon_IN IASB_NNP ,_, allowing_VBG actuarial_JJ gains_NNS and_CC losses_NNS to_TO acquisitions_NNS against_IN reserves_NNS ._.
Under_IN IFRS_NNP 1_CD As_IN noted_VBN below_IN ,_, these_DT financial_JJ statements_NNS be_VB recognized_VBN in_IN full_JJ through_IN reserves_NNS ,_, will_MD be_VB and_CC IFRS_VB 3_CD ,_, such_JJ goodwill_NN will_MD remain_VB have_VB been_VBN prepared_VBN on_IN the_DT basis_NN of_IN IFRSs_NNS endorsed_VBN by_IN the_DT EU_NNP ._.
expected_VBN to_TO be_VB available_JJ at_IN 31_CD December_NNP 2005_CD ._.
These_DT are_VBP subject_JJ to_TO ongoing_JJ review_NN AstraZenecas_NNP management_NN considers_VBZ the_DT Employee_NN benefits_NNS and_CC endorsement_NN by_IN the_DT EU_NNP or_CC possible_JJ following_VBG to_TO be_VB the_DT most_RBS important_JJ The_DT Group_NNP accounts_NNS for_IN pensions_NNS and_CC similar_JJ amendment_NN by_IN interpretative_JJ guidance_NN from_IN accounting_VBG policies_NNS in_IN the_DT context_NN of_IN the_DT benefits_NNS principally_RB healthcare_NN under_IN IAS_NNP 19_CD the_DT IASB_NNP International_NNP Accounting_NNP Groups_NNS operations_NNS ._.
In_IN respect_NN of_IN defined_VBN Standards_NNP Board_NNP and_CC are_VBP therefore_RB still_RB benefit_VB plans_NNS ,_, obligations_NNS are_VBP measured_VBN at_IN subject_JJ to_TO change_VB ._.
We_PRP will_MD update_VB our_PRP$ Revenue_NN discounted_VBD present_JJ value_NN whilst_NN plan_NN assets_NNS restated_VBN information_NN as_RB necessary_JJ for_IN any_DT Turnover_NN excludes_VBZ inter-company_JJ sales_NNS and_CC are_VBP recorded_VBN at_IN fair_JJ value_NN ._.
The_DT operating_NN and_CC such_JJ changes_NNS ,_, should_MD they_PRP occur_VBP ._.
value-added_JJ taxes_NNS and_CC represents_VBZ net_JJ financing_NN costs_NNS of_IN such_JJ plans_NNS are_VBP recognized_VBN invoice_JJ value_NN less_RBR estimated_JJ rebates_NNS ,_, returns_NNS separately_RB in_IN the_DT income_NN statement_NN :_: service_NN Basis_NN of_IN preparation_NN and_CC settlement_NN discounts_NNS ._.
Turnover_NN is_VBZ costs_NNS are_VBP spread_VBN systematically_RB over_IN the_DT lives_NNS The_DT financial_JJ information_NN has_VBZ been_VBN prepared_JJ recognized_VBN when_WRB the_DT significant_JJ risks_NNS and_CC of_IN employees_NNS and_CC financing_NN costs_NNS are_VBP in_IN accordance_NN with_IN IFRS_NNP as_IN adopted_VBN by_IN the_DT rewards_NNS of_IN ownership_NN have_VBP been_VBN transferred_VBN recognized_VBN in_IN the_DT periods_NNS in_IN which_WDT they_PRP arise_VBP ._.
The_DT accounting_NN policies_NNS applied_VBN are_VBP set_VBN to_TO a_DT third_JJ party_NN ._.
Actuarial_JJ gains_NNS and_CC losses_NNS are_VBP recognized_VBN out_RP on_IN pages_NNS 139_CD to_TO 141_CD ._.
immediately_RB in_IN the_DT statement_NN of_IN recognized_VBN Research_NNP and_CC development_NN income_NN and_CC expense_NN ._.
All_DT IASB_NNP standards_NNS in_IN issue_NN at_IN December_NNP Research_NNP expenditure_NN is_VBZ charged_VBN to_TO income_NN 2004_CD have_VBP been_VBN endorsed_VBN by_IN the_DT EU_NNP ,_, except_IN in_IN the_DT year_NN in_IN which_WDT it_PRP is_VBZ incurred_VBN ._.
Payments_NNS to_TO defined_VBN contribution_NN schemes_NNS as_IN noted_VBN below_IN :_: are_VBP charged_VBN as_IN an_DT expense_NN as_IN they_PRP fall_VBP due_JJ ._.
Internal_NNP development_NN expenditure_NN is_VBZ charged_VBN The_DT EU_NNP has_VBZ issued_VBN a_DT revised_VBN version_NN of_IN to_TO income_NN in_IN the_DT year_NN in_IN which_WDT it_PRP is_VBZ incurred_VBN Share-based_JJ payments_NNS IAS_NNP 39_CD referred_VBD to_TO as_IN the_DT carve_VBP out_RP unless_IN it_PRP meets_VBZ the_DT recognition_NN criteria_NNS of_IN IAS_NNP The_NNP fair_JJ value_NN of_IN employee_NN share_NN option_NN plans_VBZ version_NN and_CC has_VBZ endorsed_VBN this_DT rather_RB 38_CD Intangible_NNP Assets_NNPS ._.
Regulatory_NNP and_CC other_JJ is_VBZ calculated_VBN using_VBG the_DT Black-Scholes_NNP model_NN ._.
than_IN the_DT full_JJ IASB_NNP standard_NN ._.
uncertainties_NNS generally_RB mean_VBP that_IN such_JJ In_IN accordance_NN with_IN IFRS_NNP 2_CD Share-based_JJ The_DT IASB_NNP has_VBZ issued_VBN amendments_NNS to_TO criteria_NNS are_VBP not_RB met_VBN ._.
Where_WRB ,_, however_RB ,_, the_DT Payments_NNS the_DT resulting_VBG cost_NN is_VBZ charged_VBN to_TO IAS_NNP 19_CD allowing_VBG actuarial_JJ gains_NNS or_CC losses_NNS recognition_NN criteria_NNS are_VBP met_VBN ,_, intangible_JJ assets_NNS the_DT income_NN statement_NN over_IN the_DT vesting_JJ period_NN are_VBP capitalized_VBN and_CC amortised_VBN over_IN their_PRP$ of_IN the_DT options_NNS ._.
The_DT value_NN of_IN the_DT charge_NN is_VBZ References_NNS to_TO IFRS_NNP refer_VBP to_TO the_DT application_NN of_IN useful_JJ economic_JJ lives_NNS from_IN product_NN launch_NN ._.
adjusted_VBN to_TO reflect_VB expected_VBN and_CC actual_JJ levels_NNS International_NNP Accounting_NNP Standards_NNPS ,_, Payments_NNS to_TO in-license_JJ products_NNS and_CC of_IN options_NNS vesting_NN ._.
International_NNP Financial_NNP Reporting_NNP Standards_NNPS compounds_VBZ from_IN external_JJ third_JJ parties_NNS ,_, and_CC Standing_VBG Interpretations_NNS issued_VBN by_IN the_DT International_NNP Financial_NNP Reporting_NNP generally_RB taking_VBG the_DT form_NN of_IN up-front_JJ Interpretations_NNPS Committee_NNP IFRIC_NNP ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC IFRS_NNP Restatements_NNP 140_CD Form_NN 20-F_JJ Information_NN 2004_CD IFRS_NNP Restatements_NNP continued_VBD Foreign_JJ currencies_NNS Tangible_JJ fixed_VBN assets_NNS is_VBZ included_VBN in_IN the_DT Group_NNP income_NN statement_NN Profit_NN and_CC loss_NN accounts_NNS in_IN foreign_JJ currencies_NNS The_DT Groups_NNS policy_NN is_VBZ to_TO write_VB off_RP the_DT on_IN the_DT equity_NN accounting_NN basis_NN ._.
The_DT holding_NN are_VBP translated_VBN into_IN US_NNP dollars_NNS at_IN average_JJ difference_NN between_IN the_DT cost_NN of_IN each_DT tangible_JJ value_NN of_IN significant_JJ associates_NNS and_CC joint_JJ exchange_NN rates_NNS for_IN the_DT relevant_JJ accounting_NN fixed_VBN asset_NN and_CC its_PRP$ residual_JJ value_NN ventures_NNS in_IN the_DT Group_NNP balance_NN sheet_NN is_VBZ periods_NNS ._.
Assets_NNS and_CC liabilities_NNS are_VBP translated_VBN systematically_RB over_IN its_PRP$ estimated_VBN useful_JJ life_NN ._.
calculated_VBN by_IN reference_NN to_TO AstraZenecas_NNP at_IN exchange_NN rates_NNS prevailing_VBG at_IN the_DT date_NN of_IN the_DT Reviews_NNS are_VBP made_VBN annually_RB of_IN the_DT estimated_VBN equity_NN in_IN the_DT net_JJ assets_NNS of_IN such_JJ associates_NNS Group_NNP balance_NN sheet_NN ._.
remaining_VBG lives_NNS and_CC residual_JJ values_NNS of_IN and_CC joint_JJ ventures_NNS ,_, as_IN shown_VBN by_IN the_DT most_RBS individual_JJ productive_JJ assets_NNS ,_, taking_VBG account_NN recent_JJ accounts_NNS available_JJ ,_, adjusted_VBN where_WRB Exchange_NNP gains_NNS and_CC losses_NNS on_IN short_JJ term_NN of_IN commercial_JJ and_CC technological_JJ appropriate_JJ and_CC including_VBG goodwill_NN on_IN foreign_JJ currency_NN borrowings_NNS and_CC deposits_NNS obsolescence_NN as_RB well_RB as_IN normal_JJ wear_NN and_CC acquisitions_NNS made_VBD since_IN 1_CD January_NNP 1998_CD ._.
are_VBP included_VBN within_IN net_JJ interest_NN payable_JJ ._.
Under_IN this_DT policy_NN it_PRP becomes_VBZ impractical_JJ Exchange_NNP differences_NNS on_IN all_DT other_JJ to_TO calculate_VB average_JJ assets_NNS lives_VBZ exactly_RB ._.
Contingent_JJ liabilities_NNS transactions_NNS ,_, except_IN relevant_JJ foreign_JJ However_RB ,_, the_DT total_JJ lives_NNS range_VBP from_IN Through_IN the_DT normal_JJ course_NN of_IN business_NN ,_, currency_NN loans_NNS ,_, are_VBP taken_VBN to_TO operating_VBG profit_NN ._.
approximately_RB 13_CD to_TO 50_CD years_NNS for_IN buildings_NNS ,_, AstraZeneca_NNP is_VBZ involved_VBN in_IN legal_JJ disputes_NNS ,_, the_DT In_IN the_DT consolidated_JJ financial_JJ statements_NNS ,_, and_CC three_CD to_TO 15_CD years_NNS for_IN plant_NN and_CC settlement_NN of_IN which_WDT may_MD involve_VB cost_NN to_TO the_DT exchange_NN differences_NNS arising_VBG on_IN equipment_NN ._.
All_DT tangible_JJ fixed_JJ assets_NNS are_VBP Group_NNP ._.
Provision_NNP is_VBZ made_VBN where_WRB an_DT adverse_JJ consolidation_NN of_IN the_DT net_JJ investments_NNS in_IN reviewed_VBN for_IN impairment_NN when_WRB there_EX are_VBP outcome_NN is_VBZ probable_JJ and_CC associated_VBN costs_NNS subsidiaries_NNS ,_, joint_JJ ventures_NNS and_CC associates_NNS ,_, indications_NNS that_IN the_DT carrying_VBG value_NN may_MD not_RB be_VB can_MD be_VB estimated_VBN reliably_RB ._.
together_RB with_IN those_DT on_IN relevant_JJ foreign_JJ recoverable_JJ ._.
currency_NN loans_NNS ,_, are_VBP taken_VBN directly_RB to_TO reserves_NNS AstraZeneca_NNP is_VBZ exposed_VBN to_TO environmental_JJ via_IN the_DT statement_NN of_IN recognized_VBN income_NN and_CC Leases_VBZ liabilities_NNS relating_VBG to_TO its_PRP$ past_JJ operations_NNS ,_, expense_NN ._.
Assets_NNS held_VBN under_IN finance_NN leases_NNS are_VBP principally_RB in_IN respect_NN of_IN soil_NN and_CC groundwater_NN capitalized_VBN and_CC included_VBN in_IN tangible_JJ fixed_VBN remediation_NN costs_NNS ._.
Provisions_NNS for_IN these_DT costs_NNS Taxation_NNP assets_NNS at_IN fair_JJ value_NN ._.
Each_DT asset_NN is_VBZ depreciated_VBN are_VBP made_VBN when_WRB there_EX is_VBZ a_DT present_JJ obligation_NN The_DT charge_NN for_IN taxation_NN is_VBZ based_VBN on_IN the_DT over_IN the_DT shorter_JJR of_IN the_DT lease_NN term_NN or_CC its_PRP$ useful_JJ and_CC where_WRB it_PRP is_VBZ probable_JJ that_IN expenditure_NN on_IN profits_NNS for_IN the_DT year_NN and_CC takes_VBZ into_IN account_NN life_NN ._.
The_DT obligations_NNS related_VBN to_TO finance_VB leases_NNS ,_, remedial_JJ work_NN will_MD be_VB required_VBN and_CC that_IN a_DT taxation_NN deferred_VBN because_IN of_IN temporary_JJ net_NN of_IN finance_NN charges_NNS in_IN respect_NN of_IN future_JJ reliable_JJ estimate_NN can_MD be_VB made_VBN of_IN the_DT cost_NN ._.
differences_NNS between_IN the_DT treatment_NN of_IN certain_JJ periods_NNS ,_, are_VBP included_VBN ,_, as_IN appropriate_JJ ,_, under_IN items_NNS for_IN taxation_NN and_CC for_IN accounting_NN creditors_NNS due_JJ within_IN ,_, or_CC creditors_NNS due_RB after_IN Inventories_NNS purposes_NNS ._.
Full_JJ provision_NN is_VBZ made_VBN for_IN the_DT tax_NN more_RBR than_IN ,_, one_CD year_NN ._.
The_DT interest_NN element_NN of_IN Inventories_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN or_CC effects_NNS of_IN these_DT differences_NNS ._.
Deferred_JJ tax_NN the_DT rental_JJ obligation_NN is_VBZ allocated_VBN to_TO net_JJ realisable_JJ value_NN ._.
The_DT first_JJ in_IN ,_, first_RB out_IN or_CC an_DT assets_NNS are_VBP recognized_VBN to_TO the_DT extent_NN that_IN it_PRP is_VBZ accounting_VBG periods_NNS during_IN the_DT lease_NN term_NN to_TO average_JJ method_NN of_IN valuation_NN is_VBZ used_VBN ._.
For_IN probable_JJ that_IN taxable_JJ profit_NN will_MD be_VB available_JJ reflect_VBP a_DT constant_JJ rate_NN of_IN interest_NN on_IN the_DT finished_VBN goods_NNS and_CC work_NN in_IN progress_NN ,_, cost_NN against_IN which_WDT the_DT asset_NN can_MD be_VB utilised_VBN ._.
This_DT remaining_VBG balance_NN of_IN the_DT obligation_NN for_IN each_DT includes_VBZ directly_RB attributable_JJ costs_NNS and_CC requires_VBZ judgements_NNS to_TO be_VB made_VBN in_IN respect_NN of_IN accounting_NN period_NN ._.
certain_JJ overhead_NN expenses_NNS including_VBG the_DT forecast_NN of_IN future_JJ taxable_JJ income_NN ._.
Selling_VBG expenses_NNS and_CC certain_JJ Rentals_NNS under_IN operating_VBG leases_NNS are_VBP charged_VBN other_JJ overhead_NN expenses_NNS principally_RB central_JJ No_DT deferred_VBN tax_NN asset_NN or_CC liability_NN is_VBZ recognized_VBN to_TO the_DT income_NN statement_NN as_IN incurred_VBN ._.
Net_NN in_IN respect_NN of_IN temporary_JJ differences_NNS realisable_JJ value_NN is_VBZ determined_VBN as_IN estimated_VBN associated_VBN with_IN investments_NNS in_IN subsidiaries_NNS ,_, Subsidiaries_NNPS ,_, associates_NNS and_CC joint_JJ ventures_NNS selling_VBG price_NN less_RBR all_DT estimated_VBN costs_NNS of_IN branches_NNS ,_, associates_NNS and_CC joint_JJ ventures_NNS ,_, A_DT subsidiary_NN is_VBZ an_DT entity_NN controlled_VBN ,_, directly_RB or_CC completion_NN and_CC costs_NNS to_TO be_VB incurred_VBN in_IN where_WRB the_DT Group_NNP is_VBZ able_JJ to_TO control_VB the_DT timing_NN indirectly_RB ,_, by_IN AstraZeneca_NNP PLC._NNP ._.
Control_NNP is_VBZ marketing_NN ,_, selling_VBG and_CC distribution_NN ._.
of_IN reversal_NN of_IN the_DT temporary_JJ differences_NNS and_CC it_PRP regarded_VBD as_IN the_DT power_NN to_TO govern_VB the_DT financial_JJ is_VBZ probable_JJ that_IN the_DT temporary_JJ differences_NNS will_MD and_CC operating_VBG policies_NNS of_IN the_DT entity_NN so_RB as_IN to_TO Financial_NNP instruments_NNS not_RB reverse_VB in_IN the_DT foreseeable_JJ future_NN ._.
obtain_VB benefits_NNS from_IN its_PRP$ activities_NNS ._.
Financial_NNP instruments_NNS are_VBP recorded_VBN initially_RB at_IN fair_JJ value_NN ._.
Subsequent_JJ measurement_NN Accruals_NNP for_IN tax_NN contingencies_NNS require_VBP An_DT associate_NN is_VBZ an_DT undertaking_NN ,_, not_RB being_VBG a_DT depends_VBZ on_IN the_DT designation_NN of_IN the_DT management_NN to_TO make_VB judgements_NNS and_CC subsidiary_NN or_CC joint_JJ venture_NN ,_, in_IN which_WDT instrument_NN ,_, as_IN follows_VBZ :_: estimates_NNS of_IN ultimate_JJ exposures_NNS in_IN relation_NN to_TO AstraZeneca_NNP has_VBZ a_DT participating_VBG interest_NN and_CC tax_NN audit_NN issues_NNS and_CC exposures_NNS ._.
Tax_NNP benefits_NNS over_IN whose_WP$ commercial_JJ and_CC financial_JJ policy_NN Investments_NNP other_JJ than_IN interests_NNS in_IN joint_NN are_VBP not_RB recognized_VBN unless_IN the_DT tax_NN positions_NNS decisions_NNS AstraZeneca_NNP has_VBZ the_DT power_NN to_TO ventures_NNS ,_, associates_NNS and_CC fixed_VBN deposits_NNS will_MD probably_RB be_VB sustained_VBN ._.
Once_RB considered_VBN exert_NN significant_JJ influence_NN ._.
and_CC short_JJ term_NN investments_NNS other_JJ than_IN to_TO be_VB probable_JJ ,_, management_NN reviews_NNS each_DT fixed_VBN deposits_NNS are_VBP normally_RB designated_VBN material_NN tax_NN benefit_NN to_TO assess_VB whether_IN a_DT A_DT joint_JJ venture_NN is_VBZ an_DT entity_NN in_IN which_WDT as_IN available_JJ for_IN sale_NN ._.
Where_WRB the_DT exposure_NN provision_NN should_MD be_VB taken_VBN against_IN full_JJ AstraZeneca_NNP holds_VBZ an_DT interest_NN on_IN a_DT long_JJ term_NN to_TO a_DT change_NN in_IN fair_JJ value_NN of_IN such_PDT an_DT asset_NN recognition_NN of_IN that_DT benefit_NN on_IN the_DT basis_NN of_IN a_DT basis_NN and_CC which_WDT is_VBZ jointly_RB controlled_VBN by_IN is_VBZ substantially_RB offset_VBN by_IN the_DT exposure_NN to_TO potential_JJ settlement_NN through_IN negotiation_NN AstraZeneca_NNP and_CC one_CD or_CC more_JJR other_JJ a_DT change_NN in_IN the_DT fair_JJ value_NN of_IN derivatives_NNS ,_, and_CC or_CC litigation_NN ._.
Any_DT recorded_VBN exposure_NN to_TO venturers_NNS under_IN a_DT contractual_JJ arrangement_NN ._.
the_DT asset_NN is_VBZ generally_RB classified_VBN as_IN fair_JJ the_DT interest_NN on_IN tax_NN liabilities_NNS is_VBZ provided_VBN for_IN in_IN value_NN through_IN profit_NN or_CC loss_NN ._.
AstraZenecas_NNP share_NN of_IN the_DT profit_NN less_RBR losses_NNS of_IN all_DT significant_JJ joint_JJ ventures_NNS and_CC associates_NNS Fixed_VBN deposits_NNS ,_, comprising_VBG principally_RB AstraZeneca_NNP Annual_JJ Report_NNP and_CC IFRS_NNP Restatements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 141_CD funds_NNS held_VBN with_IN banks_NNS and_CC other_JJ financial_JJ In_IN addition_NN the_DT Group_NNP has_VBZ chosen_VBN to_TO restate_VB institutions_NNS ,_, and_CC short_JJ term_NN borrowings_NNS comparative_JJ information_NN with_IN respect_NN to_TO and_CC overdrafts_NNS are_VBP classified_VBN as_IN loans_NNS and_CC IAS_NNP 32_CD ,_, IAS_NNP 39_CD and_CC IFRS_NNP 2_CD ._.
receivables_NN and_CC held_VBN at_IN amortised_JJ cost_NN ._.
The_DT Group_NNP has_VBZ also_RB opted_VBN to_TO adopt_VB the_DT IASB_NNP Derivatives_NNS ,_, comprising_VBG interest_NN rate_NN amendments_NNS to_TO IAS_NNP 19_CD early_RB ,_, allowing_VBG swaps_NNS ,_, foreign_JJ exchange_NN contracts_NNS and_CC actuarial_JJ gains_NNS and_CC losses_NNS to_TO be_VB charged_VBN to_TO options_NNS and_CC embedded_VBN derivatives_NNS ,_, are_VBP reserves_NNS in_IN the_DT period_NN in_IN which_WDT they_PRP arise_VBP ._.
classified_VBN as_IN held_VBN for_IN trading_NN ._.
Changes_NNS in_IN fair_JJ value_NN are_VBP taken_VBN to_TO the_DT income_NN statement_NN ._.
Long_JJ term_NN loans_NNS are_VBP generally_RB held_VBN at_IN amortised_JJ cost_NN ._.
Where_WRB a_DT derivative_JJ financial_JJ instrument_NN generally_RB an_DT interest_NN rate_NN swap_NN hedges_NNS the_DT changes_NNS in_IN fair_JJ value_NN of_IN a_DT long_JJ term_NN loan_NN ,_, any_DT gain_NN or_CC loss_NN on_IN the_DT hedging_VBG instrument_NN is_VBZ recognized_VBN in_IN the_DT income_NN statement_NN ._.
The_DT hedged_VBN item_NN is_VBZ also_RB stated_VBN at_IN fair_JJ value_NN in_IN respect_NN of_IN the_DT risk_NN being_VBG hedged_VBN ,_, with_IN any_DT gain_NN or_CC loss_NN being_VBG recognized_VBN in_IN the_DT income_NN statement_NN ._.
Changes_NNS in_IN the_DT fair_JJ value_NN of_IN financial_JJ instruments_NNS are_VBP dealt_VBN with_IN as_IN follows_VBZ :_: For_IN available_JJ for_IN sale_NN assets_NNS ,_, exchange_NN losses_NNS and_CC impairments_NNS are_VBP taken_VBN to_TO the_DT income_NN statement_NN ._.
All_DT other_JJ changes_NNS in_IN fair_JJ value_NN are_VBP taken_VBN to_TO reserves_NNS ._.
On_IN disposal_NN of_IN the_DT related_JJ asset_NN ,_, the_DT accumulated_VBN changes_NNS in_IN fair_JJ value_NN recorded_VBN in_IN reserves_NNS are_VBP included_VBN in_IN the_DT gain_NN or_CC loss_NN recorded_VBN in_IN the_DT income_NN statement_NN ._.
For_IN long_JJ term_NN loans_NNS effectively_RB hedged_VBN ,_, assets_NNS at_IN fair_JJ value_NN through_IN profit_NN or_CC loss_NN and_CC assets_NNS held_VBN for_IN trading_NN ,_, all_DT changes_NNS in_IN fair_JJ value_NN are_VBP recognized_VBN in_IN the_DT income_NN statement_NN ._.
IFRS_NNS transitional_JJ arrangements_NNS and_CC early_JJ adoption_NN When_WRB preparing_VBG the_DT Groups_NNS IFRS_VBP balance_NN sheet_NN at_IN 1_CD January_NNP 2003_CD ,_, the_DT date_NN of_IN transition_NN ,_, the_DT following_VBG optional_JJ exemptions_NNS from_IN full_JJ retrospective_JJ application_NN of_IN IFRS_NNP accounting_NN policies_NNS have_VBP been_VBN adopted_VBN :_: Business_NNP combinations_NNS the_DT provisions_NNS of_IN IFRS_NNP 3_CD have_VBP been_VBN applied_VBN prospectively_RB from_IN 1_CD January_NNP 2003_CD :_: and_CC Employee_NNP benefits_VBZ the_DT accumulated_VBN actuarial_JJ gains_NNS and_CC losses_NNS in_IN respect_NN of_IN employee_NN defined_VBN benefit_NN plans_NNS have_VBP been_VBN recognized_VBN in_IN full_JJ through_IN reserves_NNS ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC IFRS_NNP Restatements_NNP 142_CD Form_NN 20-F_JJ Information_NN 2004_CD IFRS_NNP Restatements_NNP continued_VBD Reconciliation_NNP of_IN profit_NN IFRS_NNS 2_CD IAS_NNP 32_CD Reported_VBN ShareIAS_NNP 19_CD IAS_NNP 39_CD Restated_VBN under_IN UK_NNP based_VBN Employee_NNP Financial_NNP under_IN GAAP_NNP Payments_NNS Benefits_NNPS Instruments_NNPS Other_JJ IFRS_NNP For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Sales_NNS 21,42621,426_CD Cost_NN of_IN sales_NNS 5,150_CD 2_CD 41_CD 5,193_CD Distribution_NN costs_VBZ 177_CD 177_CD Research_NNP and_CC development_NN 3,803_CD 42_CD 1_CD 24_CD 403_CD 3,467_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ expenses_NNS 7,841_CD 103_CD 10_CD 334_CD 8,268_CD Other_JJ operating_NN income_NN 315_CD 89_CD 226_CD Operating_NN profit_NN 4,770_CD 147_CD 9_CD 154_CD 69_CD 4,547_CD Net_NN finance_NN costs_NNS 90_CD 8_CD 28_CD 1_CD 53_CD Income_NN from_IN dividends_NNS 6_CD 6_CD Profit_NN on_IN sale_NN of_IN interest_NN in_IN joint_JJ venture_NN 219_CD 219_CD Profit_NN before_IN tax_NN 5,085_CD 147_CD 1_CD 182_CD 68_CD 4,825_CD Taxation_NNP 1,254_CD 20_CD 1_CD 54_CD 66_CD 1,155_CD Profit_NN for_IN the_DT period_NN 3,831_CD 167 128 134_CD 3,670_CD Attributable_JJ to_TO :_: Equity_NNP holders_NNS of_IN the_DT Company_NN 3,813_CD 167_CD 1_CD 128_CD 134_CD 3,651_CD Minority_NNP interest_NN 18_CD 1_CD 19_CD Basic_JJ earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP $_$ 2.28_CD $_$ 0.10_CD $_$ 0.00_CD $_$ 0.08_CD $_$ 0.08_CD $_$ 2.18_CD Diluted_VBN earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP $_$ 2.28_CD $_$ 0.10_CD $_$ 0.00_CD $_$ 0.08_CD $_$ 0.08_CD $_$ 2.18_CD Statement_NN of_IN Recognised_NNP Income_NNP and_CC Expense_NNP For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2004_CD $_$ m_CD Net_JJ profit_NN for_IN the_DT period_NN 3,651_CD Foreign_NNP exchange_NN adjustments_NNS on_IN consolidation_NN 689_CD Tax_NNP on_IN foreign_JJ exchange_NN adjustments_NNS 379_CD Valuation_NN gains_NNS taken_VBN to_TO equity_NN 39_CD Actuarial_NNP gains_NNS and_CC losses_NNS ,_, net_NN of_IN tax_NN 98_CD Recognised_VBN gains_NNS and_CC losses_NNS for_IN the_DT year_NN 4,660_CD Tax_NNP on_IN foreign_JJ exchange_NN adjustments_NNS on_IN consolidation_NN in_IN 2004_CD includes_VBZ a_DT credit_NN of_IN $_$ 357m_CD in_IN respect_NN of_IN foreign_JJ exchange_NN losses_NNS arising_VBG in_IN 2000_CD ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC IFRS_NNP Restatements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 143_CD Reconciliation_NNP of_IN profit_NN IFRS_NNS 2_CD IAS_NNP 32_CD Reported_VBN ShareIAS_NNP 19_CD IAS_NNP 39_CD Restated_VBN under_IN UK_NNP based_VBN Employee_NNP Financial_NNP under_IN GAAP_NNP Payments_NNS Benefits_NNPS Instruments_NNPS Other_JJ IFRS_NNP For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Sales_NNS 18,849_CD 18,849_CD Cost_NN of_IN sales_NNS 4,469_CD 2_CD 2_CD 11_CD 1_CD 4,463_CD Distribution_NN costs_NNS 162_CD 162_CD Research_NNP and_CC development_NN 3,451_CD 42_CD 5_CD 486_CD 3,012_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ expenses_NNS 6,856_CD 110_CD 7_CD 4_CD 424_CD 7,393_CD Other_JJ operating_NN income_NN 200_CD 12_CD 188_CD Operating_NN profit_NN 4,111_CD 154_CD 14_CD 3_CD 61_CD 4,007_CD Net_NN finance_NN costs_NNS 89_CD 7_CD 24_CD 2_CD 56_CD Income_NN from_IN dividends_NNS 2_CD 2_CD Profit_NN before_IN tax_NN 4,202_CD 154_CD 21_CD 21_CD 59_CD 4,065_CD Taxation_NNP 1,143_CD 18_CD 6_CD 5_CD 85_CD 1,029_CD Profit_NN for_IN the_DT year_NN 3,059_CD 136_CD 15_CD 16_CD 144_CD 3,036_CD Attributable_JJ to_TO :_: Equity_NNP holders_NNS of_IN the_DT Company_NN 3,036_CD 136_CD 14_CD 16_CD 144_CD 3,014_CD Minority_NNP interest_NN 23_CD 1_CD 22_CD Basic_JJ earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP $_$ 1.78_CD $_$ 0.08_CD $_$ 0.01_CD $_$ 0.01_CD $_$ 0.08_CD $_$ 1.76_CD Diluted_VBN earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP $_$ 1.78_CD $_$ 0.08_CD $_$ 0.01_CD $_$ 0.01_CD $_$ 0.08_CD $_$ 1.76_CD Statement_NN of_IN Recognised_NNP Gains_NNS and_CC Losses_NNS For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2003_CD $_$ m_CD Net_JJ profit_NN for_IN the_DT period_NN 3,014_CD Foreign_NNP exchange_NN adjustments_NNS on_IN consolidation_NN 1,256_CD Tax_NNP on_IN foreign_JJ exchange_NN adjustments_NNS 66_CD Valuation_NN gains_NNS taken_VBN to_TO equity_NN 10_CD Actuarial_JJ gains_NNS and_CC losses_NNS ,_, net_NN of_IN tax_NN 167_CD Recognised_VBN gains_NNS and_CC losses_NNS for_IN the_DT year_NN 4,179_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC IFRS_NNP Restatements_NNP 144_CD Form_NN 20-F_JJ Information_NN 2004_CD IFRS_NNP Restatements_NNP continued_VBD Reconciliation_NNP of_IN equity_NN IAS_NNP 32_CD Reported_VBN IAS_NNP 19_CD IAS_NNP 39_CD IAS_NNP 12_CD under_IN UK_NNP Employee_NNP Financial_NNP Income_NNP Restated_NNP GAAP_NNP Benefits_NNPS Instruments_NNPS Tax_NNP Other_JJ under_IN IFRS_NNP As_IN at_IN 31_CD December_NNP 2004_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Assets_NNPS Non-current_JJ assets_NNS Property_NN ,_, plant_NN and_CC equipment_NN 8,083_CD 14_CD 8,097_CD Goodwill_NNP and_CC intangible_JJ assets_NNS 2,826_CD 224_CD 3,050_CD Other_JJ investments_NNS 267_CD 5_CD 262_CD Deferred_JJ tax_NN assets_NNS 548_CD 31_CD 1,016_CD 1_CD 1,594_CD 11,176_CD 548_CD 26_CD 1,016_CD 237_CD 13,003_CD Current_JJ assets_NNS Inventories_NNS 3,020_CD 3,020_CD Trade_NNP and_CC other_JJ receivables_NN 6,274_CD 720_CD 781_CD 2_CD 4,771_CD Short_JJ term_NN investments_NNS ,_, cash_NN and_CC cash_NN equivalents_NNS 5,146_CD 88_CD 5,234_CD 14,440_CD 720_CD 88_CD 781_CD 2_CD 13,025_CD Total_JJ assets_NNS 25,616_CD 172 114 235 235_CD 26,028_CD Liabilities_NNPS Current_JJ liabilities_NNS Short_JJ term_NN borrowings_NNS ,_, overdrafts_NNS and_CC current_JJ instalments_NNS of_IN loans_NNS 142_CD 142_CD Other_JJ creditors_NNS 7,640_CD 111_CD 25_CD 1,059_CD 6,445_CD 7,782_CD 111_CD 25_CD 1,059_CD 6,587_CD Non-current_JJ liabilities_NNS Loans_NNPS 1,030_CD 68_CD 1,098_CD Retirement_NNP benefit_NN obligations_NNS 1,761_CD 1,761_CD Provisions_NNS and_CC deferred_VBN tax_NN liabilities_NNS 2,207_CD 387_CD 43_CD 107_CD 8_CD 1,978_CD Other_JJ liabilities_NNS 78_CD 8_CD 86_CD 3,315_CD 1,374_CD 111_CD 107_CD 16_CD 4,923_CD Total_JJ liabilities_NNS 11,097_CD 1,263_CD 86_CD 107_CD 1,043_CD 11,510_CD Net_JJ assets_NNS 14,519_CD 1,435_CD 28_CD 128_CD 1,278_CD 14,518_CD Equity_NNP Capital_NNP and_CC reserves_NNS attributable_JJ to_TO equity_NN holders_NNS Share_NN capital_NN 411_CD 411_CD Share_NN premium_NN account_NN 550_CD 550_CD Other_JJ reserves_NNS 1,851_CD 1,851_CD Retained_VBN earnings_NNS 11,606_CD 1,417_CD 28_CD 118_CD 1,278_CD 11,613_CD 14,418_CD 1,417_CD 28_CD 118_CD 1,278_CD 14,425_CD Minority_NNP equity_NN interests_NNS 101_CD 18_CD 10_CD 93_CD Total_JJ equity_NN and_CC reserves_NNS 14,519_CD 1,435_CD 28_CD 128_CD 1,278_CD 14,518_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC IFRS_NNP Restatements_NNP Form_NN 20-F_NNP Information_NNP 2004_CD 145_CD Reconciliation_NNP of_IN equity_NN IAS_NNP 32_CD Reported_VBN IAS_NNP 19_CD IAS_NNP 39_CD IAS_NNP 12_CD under_IN UK_NNP Employee_NNP Financial_NNP Income_NNP Restated_NNP GAAP_NNP Benefits_NNPS Instruments_NNPS Tax_NNP Other_JJ under_IN IFRS_NNP As_IN at_IN 31_CD December_NNP 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Assets_NNPS Non-current_JJ assets_NNS Property_NN ,_, plant_NN and_CC equipment_NN 7,536_CD 11_CD 7,547_CD Goodwill_NNP and_CC intangible_JJ assets_NNS 2,884_CD 143_CD 3,027_CD Other_JJ investments_NNS 220_CD 7_CD 80_CD 133_CD Deferred_JJ tax_NN assets_NNS 472_CD 2_CD 1,021_CD 19_CD 1,514_CD 10,640_CD 472_CD 5_CD 1,021_CD 93_CD 12,221_CD Current_JJ assets_NNS Inventories_NNS 3,022_CD 3,022_CD Trade_NNP and_CC other_JJ receivables_NN 5,960_CD 643_CD 897_CD 4,420_CD Short_JJ term_NN investments_NNS ,_, cash_NN and_CC cash_NN equivalents_NNS 3,951_CD 200_CD 4,151_CD 12,933_CD 643 200 897_CD 11,593_CD Total_JJ assets_NNS 23,573_CD 171 195 124_CD 93_CD 23,814_CD Liabilities_NNPS Current_JJ liabilities_NNS Short_JJ term_NN borrowings_NNS ,_, overdrafts_NNS and_CC current_JJ instalments_NNS of_IN loans_NNS 152_CD 152_CD Other_JJ creditors_NNS 7,543_CD 143_CD 994_CD 6,406_CD 7,695_CD 143_CD 994_CD 6,558_CD Non-current_JJ liabilities_NNS Loans_NNPS 303_CD 303_CD Retirement_NNP benefit_NN obligations_NNS 1,528_CD 1,528_CD Provisions_NNS and_CC deferred_VBN tax_NN liabilities_NNS 2,266_CD 314_CD 61_CD 132_CD 8_CD 2,153_CD Other_JJ liabilities_NNS 52_CD 11_CD 63_CD 2,621_CD 1,214_CD 61_CD 132_CD 19_CD 4,047_CD Total_JJ liabilities_NNS 10,316_CD 1,071_CD 61 132 975_CD 10,605_CD Net_JJ assets_NNS 13,257_CD 1,242_CD 134_CD 8_CD 1,068_CD 13,209_CD Equity_NNP Capital_NNP and_CC reserves_NNS attributable_JJ to_TO equity_NN holders_NNS Share_NN capital_NN 423_CD 423_CD Share_NN premium_NN account_NN 449_CD 449_CD Other_JJ reserves_NNS 1,857_CD 1,857_CD Retained_VBN earnings_NNS 10,449_CD 1,242_CD 134_CD 18_CD 1,068_CD 10,391_CD 13,178_CD 1,242_CD 134_CD 18_CD 1,068_CD 13,120_CD Minority_NNP equity_NN interests_NNS 79_CD 10_CD 89_CD Total_JJ equity_NN and_CC reserves_NNS 13,257_CD 1,242_CD 134_CD 8_CD 1,068_CD 13,209_CD AstraZeneca_NNP Annual_JJ Report_NNP and_CC IFRS_NNP Restatements_NNP 146_CD Form_NN 20-F_JJ Information_NN 2004_CD IFRS_NNP Restatements_NNP continued_VBD Consolidated_NNP Cash_NNP Flow_NNP Statement_NNP 2004_CD 2003_CD For_IN the_DT year_NN ended_VBD 31_CD December_NNP $_$ m_CD $_$ m_CD Cash_NN flows_VBZ from_IN operating_VBG activities_NNS Operating_VBG profit_NN before_IN taxation_NN 4,547_CD 4,007_CD Depreciation_NN ,_, amortisation_NN and_CC impairment_NN 1,268_CD 1,293_CD Increase_VBP in_IN working_VBG capital_NN 9_CD 1,080_CD Other_JJ non-cash_JJ movements_NNS 326_CD 73_CD Cash_NN from_IN operating_VBG activities_NNS 6,132_CD 4,293_CD Interest_NN paid_VBN 69_CD 39_CD Tax_NNP paid_VBD 1,246_CD 886_CD Net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS 4,817_CD 3,368_CD Cash_NN flows_VBZ from_IN investing_VBG activities_NNS Disposal_NNP of_IN business_NN operations_NNS 355_CD 80_CD Movement_NNP in_IN short_JJ term_NN investments_NNS and_CC fixed_VBN deposits_NNS 1,855_CD 617_CD Purchases_NNS of_IN property_NN ,_, plant_NN and_CC equipment_NN 1,063_CD 1,282_CD Disposals_NNS of_IN property_NN ,_, plant_NN and_CC equipment_NN 35_CD 38_CD Purchase_NN of_IN intangible_JJ assets_NNS 215_CD 293_CD Purchase_NN of_IN fixed_JJ asset_NN investments_NNS 117_CD 120_CD Interest_NN received_VBD 119_CD 117_CD Dividends_NNPS paid_VBN by_IN subsidiaries_NNS to_TO minority_NN interests_NNS 5_CD 11_CD Dividends_NNS received_VBD 6_CD 2_CD Net_JJ cash_NN inflow_NN outflow_NN from_IN investing_VBG activities_NNS 970_CD 852_CD Cash_NN flows_VBZ from_IN financing_VBG activities_NNS Proceeds_NNS from_IN issue_NN of_IN share_NN capital_NN 102_CD 47_CD Repurchase_NN of_IN shares_NNS 2,212_CD 1,154_CD Increase_VBP in_IN repayment_NN of_IN loans_NNS 725_CD 345_CD Dividends_NNPS paid_VBD 1,378_CD 1,222_CD Increase_VBP in_IN short_JJ term_NN borrowings_NNS 2_CD Net_JJ cash_NN outflow_NN from_IN financing_VBG activities_NNS 2,761_CD 2,674_CD Net_JJ increase_NN decrease_NN in_IN cash_NN and_CC cash_NN equivalents_NNS 3,026_CD 158_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN the_DT beginning_NN of_IN the_DT period_NN 872_CD 968_CD Exchange_NNP movements_NNS cash_NN and_CC cash_NN equivalents_NNS 29_CD 62_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN the_DT end_NN of_IN the_DT period_NN 3,927_CD 872_CD Cash_NN and_CC cash_NN equivalents_NNS consists_VBZ of_IN :_: Cash_NN and_CC cash_NN equivalents_NNS 4,067_CD 1,024_CD Overdrafts_NNPS 140_CD 152_CD 3,927_CD 872_CD Reconciliation_NNP of_IN Net_JJ Cash_NN and_CC Debt_NN 2004_CD 2003_CD For_IN the_DT year_NN ended_VBD 31_CD December_NNP $_$ m_CD $_$ m_CD Increase_VBP decrease_NN in_IN cash_NN and_CC cash_NN equivalents_NNS 3,026_CD 158_CD Cash_NN inflow_NN outflow_NN from_IN increase_NN decrease_NN in_IN loans_NNS and_CC short_JJ term_NN borrowings_NNS 727_CD 345_CD Cash_NN inflow_NN from_IN decrease_NN in_IN short_JJ term_NN investments_NNS 1,855_CD 617_CD Change_NNP in_IN net_JJ funds_NNS resulting_VBG from_IN cash_NN flows_NNS 444_CD 430_CD Exchange_NNP movements_NNS cash_NN and_CC debt_NN 34_CD 82_CD Movement_NNP in_IN net_JJ funds_NNS UK_NNP GAAP_NNP 478_CD 348_CD Fair_NNP value_NN adjustments_NNS 180_CD 13_CD Movement_NNP in_IN net_JJ funds_NNS 298_CD 361_CD
